Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 2. Top nine proteins differentially expressed between BA and IHC.

Published byLewis Murphy Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 2. Top nine proteins differentially expressed between BA and IHC."— Presentation transcript:

1 Fig. 2. Top nine proteins differentially expressed between BA and IHC.
Top nine proteins differentially expressed between BA and IHC. Data from the discovery cohort categorized into BA (n = 35), IHC (n = 35), and age-matched normal controls (NCs; n = 9). Dots represent the log of relative fluorescent unit (RFU) for individual serum proteins. Bars and whiskers represent median and interquartile range, respectively. Q values from analysis of variance (ANOVA) with multiple hypothesis correction (Benjamini-Hochberg procedure). IGFBP-1, insulin-like growth factor-binding protein 1; ADAM9, disintegrin and metalloproteinase domain-containing protein 9; GCP-2, C-X-C motif chemokine 6; PIGR, polymeric immunoglobulin receptor; SARP-2, secreted frizzled-related protein 1. Chatmanee Lertudomphonwanit et al., Sci Transl Med 2017;9:eaan8462 Published by AAAS

Download ppt "Fig. 2. Top nine proteins differentially expressed between BA and IHC."

Similar presentations

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.
Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Fig. 1. IL-6 is associated with resistance to EGFR TKIs and is induced by stress hormones. IL-6 is associated with resistance to EGFR TKIs and is induced.

Fig. 1. IL-6 is associated with resistance to EGFR TKIs and is induced by stress hormones. IL-6 is associated with resistance to EGFR TKIs and is induced.
Fig. 3. Copy number loss as a potential resistance mechanism in an independent cohort. Copy number loss as a potential resistance mechanism in an independent.

Fig. 3. Copy number loss as a potential resistance mechanism in an independent cohort. Copy number loss as a potential resistance mechanism in an independent.
Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Fig. 3. Structure of ALS-associated RNA binding proteins.

Fig. 3. Structure of ALS-associated RNA binding proteins.
Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.

Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.
Strategy for CRISPR/Cas9-mediated genome editing in ΔEx50 mice

Strategy for CRISPR/Cas9-mediated genome editing in ΔEx50 mice
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
Fig. 4. Functional annotation of VUS in EGFR.

Fig. 4. Functional annotation of VUS in EGFR.
Fig. 1. Schematic representation of the MANO method.

Fig. 1. Schematic representation of the MANO method.
Fig. 3. 3RMR response to graded ischemia ex vivo.

Fig. 3. 3RMR response to graded ischemia ex vivo.
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.
Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.
Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.
Fig. 1 DMF promotes viral infection.

Fig. 1 DMF promotes viral infection.
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.

Similar presentations

Ads by Google